Vital Signs

This issue of Vital Signs, released on May 24, 2011, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharmaceuticals and Biotechnology, Medical Devices, Telehealth, and Medical Imaging.

This issue of Vital Signs, released on May 24, 2011, provides a strategic insight on the future of pay for performance scenario in healthcare. Additionally, a company spotlight is provided for Valor Medical. Valor Medical has developed a cyanoacrylate monomer to treat cerebral aneurysms. Neucrylate AN will polymerize from a liquid to a sponge...

This issue of Vital Signs, released on May 9, 2011, provides a strategic insight on the future of neurological drugs market. Additionally, a company spotlight is provided for AcelRx, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. Reimb...

This issue of Vital Signs, released on April 25, 2011, provides analyts's summary of the American Association of Cancer Research (AACR) annual meeting. Additionally, a company spotlight is provided for QuantaLife, a venture-backed startup company based in Pleasanton, Calif., developing third-generation of Polymerase Chain Reaction (PCR) technol...

This issue of Vital Signs, released on April 19, 2011, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharmaceuticals and Biotechnology, Medical Devices, In Vitro Diagnostics, Telehealth, Healthcare IT and Life Science Research Tools.

This issue of Vital Signs, released on April 11, 2011, provides a strategic insight on the telehealth market. Additionally, a company spotlight is provided for Cardiocom, a company that prominently works on diabetes and cardiac monitoring solutions. Reimbursement and regulatory news from the FDA is also provided for week of March 21, 2011.

This issue of Vital Signs, released on March 31, 2011, provides a strategic insight on the vaccines market. Additionally, a company spotlight is provided for Health Decisions, a CRO that has built a flexible global trial network that offers a structured, technology-backed clinical trial management model that focuses on improving speed and produ...

This issue of Vital Signs, released on March 21, 2011, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharmaceuticals and Biotechnology, Medical Devices, In Vitro Diagnostics and Life Science Research Tools.

This issue of Vital Signs, released on March 14, 2011, provides a strategic insight on the mergers and acquisitions activity in healthcare markets in 2010. Additionally, a company spotlight is provided for GI Dynamics, an early stage medical device company that is developing novel approaches to treat obesity.Reimbursement and regulatory news from t...